Radio Astronomy

Contains reports on four research projects.Joint Services Electronics Program (Contract DAAB07-71-C-0300)California Institute of Technology (Contract 952568)National Aeronautics and Space Administration (Contract NAS1-10693)National Science Foundation (Grant GP-21348A#2

Radio Astronomy

Contains reports on three research project.National Science Foundation (Grant GP-21348A#2)California Institute of Technology (Contract 952568)National Aeronautics and Space Administration (Grant NGR 22-009-421)U. S. Air Force - Electronic Systems Division (Contract F19628-73-C-0196

Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: Subgroup analysis of the DISTINCT randomised trial

The DISTINCT study (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) investigated the efficacy and safety of nifedipine GITS/candesartan cilexetil combinations vs respective monotherapies and placebo in patients with hypertension. This descriptive sub-analysis examined blood pressure (BP)-lowering effects in high-risk participants, including those with renal impairment (estimated glomerular filtration rate<90 ml min-1, n=422), type 2 diabetes mellitus (n=202), hypercholesterolaemia (n=206) and cardiovascular (CV) risk factors (n=971), as well as the impact of gender, age and body mass index (BMI). Participants with grade I/II hypertension were randomised to treatment with nifedipine GITS (N) 20, 30, 60 mg and/or candesartan cilexetil (C) 4, 8, 16, 32 mg or placebo for 8 weeks. Mean systolic BP and diastolic BP reductions after treatment in high-risk participants were greater, overall, with N/C combinations vs respective monotherapies or placebo, with indicators of a dose-response effect. Highest rates of BP control (ESH/ESC 2013 guideline criteria) were also achieved with highest doses of N/C combinations in each high-risk subgroup. The benefits of combination therapy vs monotherapy were additionally observed in patient subgroups categorised by gender, age or BMI. All high-risk participants reported fewer vasodilatory adverse events in the pooled N/C combination therapy than the N monotherapy group. In conclusion, consistent with the DISTINCT main study outcomes, high-risk participants showed greater reductions in BP and higher control rates with N/C combinations compared with respective monotherapies and lesser vasodilatory side-effects compared with N monotherapy

STATE EXPERIENCES IN AREA DEVELOPMENT: ALABAMA, ARKANSAS, MICHIGAN

Community/Rural/Urban Development,

Analysis of Temporal Variability in Hydrogeochemical Data Used for Multivariate Analyses

During the time over which the data for a regional hydrogeochemical survey are collected, the physical and chemical attributes of the ground-water flow regime may exhibit appreciable temporal variation. A case study is presented in which the temporal variance of many physical and chemical attributes of ground water at single locations was close to or even exceeded the spatial variance of concentrations measured over the region at a single point in time. Thus, the results of a multivariate analysis of the spatial variability could have led to incorrect inferences had the regional sampling not been done within a period of time that was short enough so that no appreciable temporal variation occurred. A methodology using both spectral and multivariate analyses was used in determining: (a) the window of time allowable in collecting the water samples so that the temporal variability of the attributes did not affect the spatial analyses, and (b) the dominant factors that explain the spatial variability of physical and chemical attributes at that particular period in time